Sara Ahnström
COO
Replay available
Apotea (Stockholm:APOTEA) Q4 2024 earnings call, held 2025-02-06. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/apotea-ab-apotea-q4-2024-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good morning everyone and welcome to Apotea's presentation of our fourth quarter report. This is also our first report as a listed company which we are very excited about of course. We will present today from our head office here in Stockholm and we will start with the presentation and then after the presentation is finished we will move on to a Q&A with spoken questions. Today's presenters will be Per Svadsson, our CEO and co-founder, together with Johan Mohild, our CFO, and together with myself, Sara Ahnström, COO.
0:42 So, hello. I think we had a very good quarter and with strong growth and increased profitability and we started also a lot of exciting projects so I think we're well prepared for the future but Johan let's guide us into the figures yes we had revenues of 1.7 billion in the quarter and growth of 15.8% the adjusted EBIT margin was 3.9% and we had a sustained high inventory turnover of close to 10x And if we look a little bit on this quarter, I mean, I think you know that we had a successful IPO in December and we welcomed more than 90,000 new owners and we're very proud of that.
1:36 We also worked quite hard to increase our Rx capacity. that's important because to sell prescription medicine we need to have capacity because we have a lot of demand out there but we need to have this capacity and we focused on building this capacity and I think when we move forward and look into the figures we can see that the growth of the prescription is very high and that's because of this. And we took actually a new record with almost 20,000 orders in just one day. Another thing is that our Varberg project, we start to install the automation in Varberg in October. And you can really see, we visited Varberg just a few weeks ago, and it's fantastic to see.
2:37 So it's on track.
2:41 Yes, a key event of the quarter was also our Black Week campaign, and we were very happy to see that it was successfully executed, much due to our increased capacity, hence also our increased automation. And during these intense days, we also delivered up to close to, I would say, 90,000 orders in a day. We have also focused quite a lot still in expanding our assortment and we currently have the largest assortment of pharmacy products in the market, close to 53,000 products. We also launched several new products over our own products during the quarter and ended the year with 270 own private label products for sale on our site.
3:29 Yes, we had revenue growth of 15.8% in the quarter and the growth was driven by strong Rx growth and as Per mentioned the growth was driven by an increased capacity in this field and to some extent media reporting at the very end of the year about changes in the high cost coverage. We see a very strong underlying demand in buying prescription based medicine online and building up our capacity in Rx is important for us to capture that demand. As you can see on the right hand side we had stable gross margin in the quarter more or less in line with the same period last year. We had adjusted EBIT margin in Q4 of 3.9% and the adjustments here are related to the cost associated with the IPO in December.
4:17 The EBIT margin in Q4 was 3%. We have seen an increased profitability and that is due to increase in sales in combination with increased fulfillment efficiency and lower freight cost in relation to sales. We have continuously been able to improve our efficiency in our fulfillment following the additional automation launched in Morongova spring of 2023. Let's take a deeper look at investments and cash flow. We had stable investment levels in Q4 and investments relate mainly to our new fulfillment center in Varberg. We had lower operating cash flow in the quarter and that is due to an increase in account receivables to the Swedish state related to the Swedish to the subsidy of prescription based medicine.
5:11 Networking capital, there are short term variations and quarterly variations in networking capital. If you take a longer view on this and look at the full year, we have a stable operating cash flow and we have a stable operating cash flow model with a high inventory turnover.
5:30 Yes, and we will now move on to look at the full year of 24. We had a very exciting year with a strong growth and improved profitability. And as a reminder, some highlights from the year. We started the quarter with a construction start of our new fulfillment center in Varberg, the actual building that we are renting. During the second quarter, we intensified the IPO preparations. We also welcomed new board members, including our chairman of the board, Cecilia Quist. During the third quarter, we had the AI department that was launched, which we are very excited about. They also initiated their first AI projects within that department. And Q4 was of course about the completion of our successful IPO.
6:17 and if we look at the whole year we can also see that we have a strong demand to buy pharmacy products online and an increasing demand so the market the online penetration went up to 23 percent the new high score and our market share in the total market is 10 percent so I think we can see a strong growth in demand online, and it's predicted to grow like 50% in coming years. So we look forward to that. And I mean, we have built the new automation in our current warehouse from 60 to 100,000 orders, and we can see how that affects us. And it's very positive for our growth.
7:08 And it's very good. And we look forward to Varberg.
7:12 Last year, we had growth of 20%. We had strong Rx growth and we had solid growth in over the counter products and traded goods. As Per mentioned, we increased our market share to 10%. On the right hand side, you can see that we strengthen our gross margin and it was counted to 27.3% due to active procurement category monitor monitoring and increased market marketing compensation from our suppliers. And the strength in gross margin was one of the drivers for the improved profitability last year. We more than doubled the adjusted EBIT margin from 2.1% to 4.4%. And the adjustments here relate to the cost associated with the IPO in December.
8:00 The EBIT margin for 24 was 4.1%. And the improved profitability was also supported by an increased efficiency, which is evident when looking at the right hand side of this slide where you can see an increased fulfillment efficiency as a result of the increased automation. Last year, we invested 163 million and the investment relate mainly to our new fulfillment center in Varberg. We were able to finance by and large this investment from our own operating cash flow and the cash flow 24 compared to a year earlier were stable. and we had a stable inventory turnover level of 9.8 times.
8:47 We've seen the inventory increase likely during 24 from a low point in December 23. We believe the inventory is now in a better balance, enabling close to the full assortment, being in stock at all times and enabling fast deliveries to our customers. We had an increased return on capital employed last year, and it increased significantly to 34.5%. And that was driven by an increase in profitability. Finally, when looking at the right hand side of this slide, you can see that we have a solid balance sheet. And despite large investments in our new fulfillment center in Varberg, we have a continued low net depth in relation to EBITDA.
9:41 Yeah, and if we look a little bit forward, 2025, we can see that we will continue to work with our RX capacity. So we are opening a new hub in the south part of Stockholm. It's more like a small warehouse where we can hire more pharmacists so we can grow the capacity. and we will open that in the second quarter we will also continue to hire more pharmacists and then we need this hub for that expand as Sara mentioned the private label assortment we want to build up here with strong brands together with private label so we can help the customer what they want but we can also increase the gross margin with selling our own products with quite often twice the margin so we have built and produced a lot of products and now it's time to sell them but we also have a lot of products in the pipeline in design or in production so we will launch a lot of new products next year or this year We said that we launched AI department 24 and now the team is complete and started to working
11:13 and now it's time to launch all these projects and actually we have I think three projects up and running but they are like still in some kind of test phase but I can really see areas where we can improve both efficiency and sales and inventory and stuff like that with help of AI. So really look forward to that. We also have, we mentioned also the Valberg facility. I mean, we started to build the building a little bit more than one year ago. and we received the key in January this year so now the building is up and running the automation we start to install the automation in the beginning of fourth quarter and we will start testing the automation in April and launch the facility in in the summer and start sending orders from Varberg in this summer and that will help us to both increase our capacity build RX capacity so we can sell more prescriptions but we can also deliver orders to the west coast same day and that's very important for our customers and we will decrease our costs because the level of automation is much
12:47 higher in Varberg compared to Morungova. So we really look forward to that and as I mentioned before, I think we're well prepared for the future and we're well prepared to meet our customer and together with our customer build the pharmacy of tomorrow. So thank you.
13:10 Perfect. That was also the last slide of the presentation, and we will open up for Q&A with spoken questions. The next question comes from Fredrik Iversen from ABG Sundell Collier. Please go ahead.
13:32 Thank you so much. Good morning, guys. Thanks for the presentation. I have three questions. I'll take them one by one. And the first one is on the sales momentum in Q4. You stated in the report that you grew strongly during black week. So can you give some color to this statement? Like what was the growth during this week? Was it significantly higher than the full quarter? Or any color to this statement would be helpful.
14:04 I can start I think we had a very good black week I mean we had a very nice black week 23 as well and I think the best thing for me at least with black week was that we could deliver the order very fast so our automation it was up and running really smooth and in just like one day after the black week was finished we were like in every order was delivered and so it was a good black week for us and a new high score as well but the most important thing was we could deliver our orders very good to our customers I agree exactly
14:55 Okay, fair enough, thanks. Second one on the gross margin. Can you help me out a little bit with the bridge here? So you said obviously Black Week was strong, which I guess weighed a little bit on margin, and then the RX share of total sales obviously grew quite hefty as well. I think it was four percentage points higher than last year, and that's obviously margin dilutive as well. Still, the margin was almost flat versus Q4 last year. So what were the positive drivers to the gross margin in Q4, please?
15:34 I mean, by and large, we had a slight, I mean, stable gross margin and a slightly higher gross margin in OTC and traded goods. Because as we mentioned, the higher share of RX is
15:53 pulling the the gross margin overall a bit little bit down so and we try to stabilize the gross margin and then we have we watch the prices every day every section so we try to stabilize them and have like a gross margin goal and try to reach that level so I mean if one sales go up and now they go down and so on we try to stabilize it over time
16:27 Okay, so the higher gross margin in OTC and traded goods were to some extent price driven. That's what you're saying, I guess.
16:36 I mean, we also get contribution from our suppliers and we negotiate the prices with the suppliers and negotiate campaigns and so on. So we try to not raise the price. We try to lower our cost instead. Yes.
16:52 But it's important to keep a close look on the margins at all times. I mean, if you have an assortment of $53,000 articles, you need to calibrate up and down a
17:08 little. Thanks. And last question from my side. On the new prescription hub you're opening in Stockholm June Q2, what is the capacity of this new hub in terms of number of pharmacists?
17:25 I think we can have like 30 pharmacists working there but I mean you can always work during evenings and then you have another 30. You can work during weekends and so on so it's not that this is the capacity but from start we will be like maybe 15 to 20 pharmacists working there from day one but over time we can absolutely increase that number
17:54 I think just as a comment, we are not really using the full capacity of the rest of the RxHubs or our facilities. So this is also for the purpose of the future growth, but also for the purpose of actually recruiting more pharmacists. So we think that this is a quite attractive area also for recruitment and building capacity for the future.
18:18 Perfect. That's my question. Thanks so much.
18:21 Thank you. The next question comes from Johan Fred from SEB. Please go ahead.
18:33 Hi, good morning guys and congratulations on your first quarter as a listed company. A first one from my side on other products. Sales growth was a bit slower than in prior quarters. Is there a specific reason for the slowdown? Was it due to, for example, tough competition from peers during Black Week? Or is this an impact from your efforts to drive sales in RX?
19:01 I think if you look at just one quarter, it's a little bit different. too short period to do to really say I mean what do you compare with last year and so on and we can see a strong growth on traded goods so I think over time we will have a strong growth in that area and but don't just look at one quarter because it's too short
19:30 Okay, got it. So nothing in particular there, just a tough comps. Okay, so could you provide any insights into the split between OTC and traded goods in the quarter?
19:44 I don't have that number actually in front of me. I think it's fairly stable compared to what we have stated before.
19:50 Yeah, we handle traded goats and OTC the same, so we don't really follow it. But we, I would say, haven't changed, but we don't follow it.
20:05 No, but I would assume the margin profile on the two categories are quite different, right?
20:11 No, they are very similar. So that's why we're not following it because we buy them, we purchase them the same, we sell them the same and almost every aspect is the same.
20:28 Okay, got it. And you stated that you intended to or you intensified your efforts to recruit pharmacists during the autumn and now during Q4 as well. How many pharmacists do you have on staff currently and what's sort of your trajectory for recruitment going into 2025?
20:51 I think I wouldn't give an exact figure to that, but I think we've been quite active in recruiting pharmacists for the full year or for the full half year. during the fall and during the winter. And I think that we have been quite successful. So we are looking quite positive on the future that we have the capacity to kind of grow the Rx even more. And we will continue to recruit in order to fulfill the targets for the Rx sales as well. But yeah, so we're quite pleased with the number of pharmacists we have today. And we will continue to recruit to make sure that we can grow as much as we want in the future as well.
21:37 And how many pharmacists do you have today?
21:40 Sorry? How many? I don't have the exact figure, but we are, I mean, if we last summer started with 120, we are at a significant high number, and I think we will reach 200 during 25. But, I mean, we have...
22:02 Thank you so much. And the final one on... Okay, thank you so much. And the final one from my side. Could you provide any insights as to the potential costs relating to the expansion of the new RX hub in south of Stockholm, please?
22:27 it's quite low I mean it's no heavy investments just a few shelves and we have these shelves already in our Morongoa facility so it's more like cost for the pharmacist and that's like just the salary cost so the investment cost is very very low.
22:56 Exactly I think also the cost for the rest in comparison to the to the warehouse in Morongova and Varberg and also in comparison to the inventory levels they are very small in comparison so it's also the ongoing costs are quite low in comparison.
23:14 Okay got it thank you those were all of my questions for now thank you so much. Thank you. The next question comes from Victor Carnegie. Please unmute your microphone.
23:30 Hi, guys. Good morning. Thank you for taking my questions. This is Victor Hansen from Carnegie. So I was curious about Norway. You saw nice growth here. I believe it was 18%, if I recall correctly, at least for the full year. So I'm curious here, what sales levels do you believe you need in order to reach profitability? And how do you prioritize currently sales growth versus profitability? Because I know, for instance, that you're five times larger, roughly five times larger competitor isn't profitable either in Norway.
24:08 I would say for the we have had some months of profitability have been quite or very much on the not losing money for months in Norway so we feel quite comfortable that we are soon reaching the level of profitability and that's also the ambition for 2025. So we're close in getting there and I think we have really prioritized also the profitability during the last year, during 2024 and our ambition for 2025 is to of course grow but being profitable during the year.
24:43 And I think the Apothea way of doing it is that you are profitable and then you start growing because I think as you can see these competitors that is unprofitable and continue to grow with the low margins it's quite complicated to change from just growing to profitability It doesn't help if you're big, if you lose money on every order. So I think it's much better to start with profitability and then focus on growing. And we are quite close to changing from profitability to growing because we are very close to profitability.
25:30 Okay, perfect. So despite there being less people in Norway and the more a longer country geographically. So you see lower population density basically. You see no problem in becoming profitable. Good. I have a second question that's on beauty sales. You have about 1 billion in beauty sales just above that. So I was curious how you view the competition in this category, online channel.
26:04 I think it's similar to other categories I mean it's high competition in all the categories and we like that and but of course if you have these traded goods and then beauty you can find skin care in a lot of different channels but you can also find toothpaste in a lot of different channels so I think it's a little bit the same or
26:30 Yes, I think we also try to try to expand the assortment in a logical way for us, continuing being a pharmacy, but will be perceived as a pharmacy, but also growing into new categories. And I think beauty has become a focus area going forward. We are also we have a decent amount of sales in beauty already, but we also want to continue to focus to focus on it. And
26:54 Yeah, okay. Sounds exciting. Then a final question here from my side on cash flow. You built some working capital in Q4. Of course, that could be driven by higher sales. But is there something specific in Q4 causing you to build additional working capital? Or should we perhaps expect it to reverse in the first half of 25? Or how do you view the working capital?
27:22 I believe long term we have a stable operating cash flow model. And the change in Q4, I mean, there are ups and downs in the net working capital in the short term and in the quarter. Specifically, we had an increase in the account receivables. So I wouldn't expect in a major or I would expect the cash flow model to be by and large stable going forward in a long term perspective.
27:53 Okay, thank you very much. That's all for me. Thank you. Thank you.
27:58 Perfect. Thank you. And thank you for all your questions. That was also the last one of today. So thank you for listening to our fourth quarter report and we wish you all a pleasant day.
28:08 Thank you very much. Bye.
Follow Apotea AB into a list and get an email when it puts out news.
COO
CEO & Co-founder
CFO
Analyst, ABG Sundal Collier
Analyst, SEB
Analyst, Carnegie